Carbapenems are important agents for the therapy of infections due to multidrug-resistant Pseudomonas aeruginosa; the development of carbapenem resistance hampers effective therapeutic options. To assess the mechanisms leading to resistance, 33 clinical isolates with differing degrees of carbapenem susceptibility were analyzed for the expression of the chromosomal ␤-lactamase (ampC), the porin that is important for the entry of carbapenems (oprD), and the proteins involved in four efflux systems (mexA, mexC, mexE, and mexX). Real-time reverse transcriptase PCR was performed using primers and fluorescent probes for each of the target genes. The sequencing of regulatory genes (ampR, mexR, nalC, nalD, mexT, and mexZ) was also performed. Diminished expression of oprD was present in all imipenem-and meropenem-resistant isolates but was not required for ertapenem resistance. Increased expression of ampC was not observed in several isolates that were overtly resistant to carbapenems. Increased expression of several efflux systems was observed in many of the carbapenem-resistant isolates. Increased efflux activity correlated with high-level ertapenem resistance and reduced susceptibility to meropenem and aztreonam. Most isolates with increased expression of mexA had mutations affecting nalC and/or nalD. Two isolates with mutations leading to a premature stop codon in mexZ had markedly elevated mexX expressions, although mutations in mexZ were not a prerequisite for overexpression. ␤-Lactam resistance in clinical isolates of P. aeruginosa is a result of the interplay between diminished production of oprD, increased activity of ampC, and several efflux systems.
Both acquired and intrinsic mechanisms of antibiotic resistance make Pseudomonas aeruginosa a formidable nosocomial pathogen (19) . Carbapenem antibiotics remain important agents for the therapy of serious infections due to multidrug-resistant P. aeruginosa; the development of carbapenem resistance severely compromises effective therapeutic options. In the absence of carbapenem-hydrolyzing enzymes, the mechanism leading to carbapenem resistance is usually multifactorial. Increased chromosomal cephalosporinase activity, reduced porin expression, and augmented antibiotic extrusion have all been defined as contributory factors (18, 19) . The outer membrane protein OprD allows entry of carbapenems, and its reduced expression is frequently noted in carbapenem-resistant isolates (18, 33) .
Several antibiotic efflux systems that belong to the resistance-nodulation-division family and contribute to multidrug resistance have been characterized in P. aeruginosa. The MexAB-OprM system is constitutively expressed in virtually all isolates, and substrates for this pump include fluoroquinolones, tetracycline, chloramphenicol, and ␤-lactams (including carbenicillin, piperacillin, ceftazidime, cefepime, and aztreonam) (17, 27, 40, 46, 50) . Imipenem does not appear to be a substrate for MexAB-OprM, but because of its hydrophobic side chain, meropenem can be affected by this system (13, 17, 33) . The expression of the MexAB-OprM system is negatively controlled by the repressor MexR, and derepression of the mexAB-oprM operon may be caused by mutations in the mexR gene (1, 5, 22, 37, 39, 40, 46, 51) . However, it is evident that other control mechanisms are involved in mexAB-oprM expression (22, 24, 37, 42, 46, 51) . Mutational inactivation of a second regulatory gene, nalC, increased the expression of an ill-defined protein, PA3719, which then increased MexAB-OprM expression (4) . Although selected mutations have been observed in clinical isolates, the same mutations have also been observed in wild-type strains (22) . A third regulatory gene of the mexAB-oprM operon, nalD, has also been identified; mutations in this gene have been observed in clinical isolates overexpressing MexAB-OprM (43) .
Fluoroquinolones and the antipseudomonal ␤-lactams piperacillin, cefepime, and meropenem (but not carbenicillin, aztreonam, ceftazidime, or imipenem) are substrates for the MexCD-OprJ system, although this efflux pump is not typically expressed under normal growth conditions (27, 36) . A third efflux system, MexEF-OprN, can export fluoroquinolones, trimethoprim, and chloramphenicol and is positively regulated by mexT (12, 14, 26) . Although mutations converting MexT from nonfunctional to functional have been recovered in isolates overexpressing mexEF-oprN, in some isolates, no changes have been detected (12, 25) . The disruption of a second recently described regulator, MexS, can also increase the expression of mexEF-oprN (45) . MexT can also function as a negative regulator for the expression of other proteins, including OprD (mediating imipenem resistance) and MexAB-OprM (leading to ␤-lactam hypersusceptibility) (12, 24, 32) . Finally, MexXYOprM expression can be induced with growth in tetracycline or aminoglycosides (2, 28, 29) . MexXY-OprM may contribute to fluoroquinolone, aminoglycoside, and selected ␤-lactam (piperacillin, cefepime, and meropenem but not carbenicillin, ceftazidime, or imipenem) resistance (2, 27, 29, 44, 48) . The expression of mexXY is negatively regulated by the mexZ gene.
Mutations involving mexZ have been noted in clinical isolates overexpressing MexXY that were obtained from patients with cystic fibrosis (47) . However, not all isolates with increased expression of mexXY carry mutations in mexZ, suggesting that other regulatory mechanisms are involved (44, 47) . Antibiotics that inhibit ribosomal function have also been found to induce mexXY expression, although additional mechanisms may be involved (10) .
Virtually all studies examining the mechanisms of carbapenem resistance in P. aeruginosa have involved carefully controlled laboratory-derived strains. Studies involving clinical isolates have not clearly defined the contributions of the AmpC cephalosporinase, porin defects, and efflux systems in carbapenem resistance (9, 15, 33, 51) . Indeed, the transcriptional responses of clinical isolates to carbapenem exposure have been described as "unpredictable and chaotic" (15) . In this report, we examine the mechanisms of carbapenem (and in particular, ertapenem) resistance in clinical isolates of P. aeruginosa from New York City. studies are given in Table 1 . Real-time RT-PCR experiments were performed using the Brilliant quantitative RT-PCR master mix (Stratagene). Samples were run in triplicate and contained 50 ng of RNA per reaction. Virtually all individual results were within 0.5 cycle threshold units of the average triplicate value. Controls run without reverse transcriptase confirmed the absence of contaminating DNA in any of the samples. For the probes, the reporter dye was 6-carboxyfluorescein (DFAM) and the quencher dye was 6-carboxytetramethylrhodamine (DTAM); carboxy-X-rhodamine was included as a reference dye. Primer and probe concentrations were adjusted to provide amplification efficiencies of approximately 90 to 110% for all experiments. The expression of mRNA for the genes of interest was normalized to that of the housekeeping gene rpoD. This gene has been demonstrated to be consistently expressed in P. aeruginosa (41) , and preliminary experiments demonstrated stable expression in our isolates (data not shown). Normalized expression of each gene of interest was calibrated against corresponding mRNA expression by P. aeruginosa ATCC 27853; results are given as the relative expression of the mRNA compared to that of P. aeruginosa 27853.
To insure that nonspecific amplification did not occur, products were resolved on a 1% agarose gel and stained using ethidium bromide. No additional PCR products were noted for any of the reactions.
Regulatory gene studies. To search for possible mutations affecting important regulatory genes, the following genes were sequenced: ampR, mexR, nalC, nalD, mexT, and mexZ. The primers used to amplify and sequence the regulatory genes and the intergenic regions are listed in Table 1 . For mexR and mexT amplifications, the PCR conditions were 95°C for 15 min followed by 35 cycles of 95°C for 30 s, 56°C for 90 s, and 72°C for 60 s; this was followed by a final extension at 72°C for 10 min. PCR conditions for the amplification of nalC included 94°C for 10 min followed by 30 cycles of 95°C for 60 s, 56°C for 60 s, and 72°C for 60 s; this was followed by a final extension at 72°C for 10 min. Conditions for the amplification of ampR, nalD, and mexZ were as previously described (3, 43, 44) . For selected isolates, amplification of the oprD gene was performed by using previously established primers and conditions (35) .
Amplified products underwent bidirectional sequencing using the automated fluorescent dye terminator sequencing system (Applied Biosystems, Foster City, CA). Sequences were compared to those of the PAO1 strain of P. aeruginosa by using the BLAST program from the National Center for Biotechnology Information (www.ncbi.nlm.nih.gov/BLAST/). Sequences of mexT were compared to the genomic sequences of PAO1 characterized by Kohler et al. (12) .
Statistical methods. Fisher's exact test and Student's t test were used to compare groups. A two-tailed P value of Յ0.05 was considered significant. For statistical analysis, the following values were considered to represent overexpression compared to the control strain: for ampC, Ն10-fold; for mexA, Ն2-fold, and for mexX, Ն10-fold. These values are within the ranges noted in other studies (9, 22, 33, 49) . This study was approved by the Institution Review Board at SUNY-Downstate.
RESULTS AND DISCUSSION
The 33 clinical isolates originated from eight different hospitals in Brooklyn, NY. Susceptibility results, ribotyping data, and genetic expression data (relative to control strain P. aeruginosa ATCC 27853) are given in Table 2 . Based on the RT-PCR results, isolates were placed into three groups.
Group 1 isolates were those with diminished oprD and increased ampC expression. Diminished OprD production was defined primarily according to the real-time RT-PCR studies. For the isolates that failed to have amplification of oprD, the presence or absence of an ϳ46-kDa protein by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) of outer membrane proteins was used to classify isolates. Group 2 isolates were those with diminished oprD and unchanged ampC expression, and group 3 isolates were those with unchanged oprD and unchanged ampC expression.
Nineteen ribotypes were identified. Eight isolates belonged to ribotype A; five of the eight were nonsusceptible to all three carbapenems. Three ribotypes consisted of three isolates each, 1 ribotype had two isolates, and the remaining 14 ribotypes had one isolate each.
␤-Lactamase studies. Most isolates demonstrated a ␤-lactamase with a pI of Ͼ8, which is consistent with the class C chromosomal cephalosporinase. Seven of the eight isolates belonging to ribotype A possessed additional ␤-lactamases with pI values of 7.2 and 7.8. These ␤-lactamases did not amplify with primers specific for the TEM-, SHV-, IMP-, VIM-, and OXA-type enzymes. None of these isolates demonstrated spectrophotometric evidence of carbapenem-hydrolyzing activity (data not shown); the identification of these ␤-lactamases remains unknown. One additional isolate possessed a ␤-lactamase with a pI of 5.4; this enzyme was subsequently identified as TEM-1. a For two isolates with nonamplifiable oprD, the nucleotide sequence corresponding to the forward primer was (changes underlined) GGGCCTCTACGGCGAG GAC; that corresponding to the reverse primer was GGCCGGCCTGGACGACGTACT; and that corresponding to the probe was CACCACGAGACCAACCTG GAAGCC.
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Porin OprD studies. Seven isolates, including four that were susceptible to the three carbapenems, did not have detectable oprD mRNA expression. Amplification of the entire oprD gene from template DNA, using primers distinct from the internal primers used for the RT-PCR studies, was unsuccessful in five isolates, suggesting the presence of multiple mutations in this gene. Two isolates without detectable oprD mRNA expression had the entire oprD gene amplified and sequenced. Mutations were evident in the region targeted by the RT-PCR primers (Table 1) . Therefore, for these seven isolates with undetectable mRNA oprD expression, it is likely that mutations in the oprD gene prevented the measurement of expression. Isolates also had OprD production assessed by SDS-PAGE of outer membrane proteins; 13 of the 14 imipenem-nonsusceptible isolates lacked an ϳ46-kDa protein, which is compatible with OprD (the one isolate with this protein had an MIC of imipenem of 8 g/ml). Of the seven isolates that had nonamplifiable oprD genes during the RT-PCR studies, five were susceptible to carbapenems and had the 46-kDa protein by SDS-PAGE. The other two isolates were nonsusceptible to imipenem and lacked this protein.
Relationship of carbapenem resistance with OprD, AmpC, and efflux pump activity. Nineteen isolates were considered to have reduced oprD expression, including 17 isolates with relative oprD expressions of Յ70% of those of P. aeruginosa ATCC 27853 and two isolates with nonamplifiable oprD and the absence of the 46-kDa protein as shown by SDS-PAGE (Table  2 ). All 17 isolates that were nonsusceptible to imipenem and/or meropenem had reduced expressions of oprD relative to 2 of 16 isolates that were susceptible to both antibiotics (P Ͻ Table 2 ) also had increased ampC expression. All 13 were resistant to ertapenem, and 10 and 9 were nonsusceptible to imipenem and meropenem, respectively. Most group 1 isolates had increased mexX and some had increased mexA expression, although their contributions to carbapenem resistance are difficult to assess in this group. Nine and 12 isolates were resistant to ceftazidime and cefepime, respectively, but only 6 were resistant to aztreonam. The six aztreonam-resistant isolates were more likely to have increased expression of mexA than were the seven susceptible isolates (P ϭ 0.005).
Six isolates (group 2) ( Table 2 ) had diminished oprD activity without increased expression of ampC. Five of the six were nonsusceptible to imipenem and/or meropenem, and all were resistant to ertapenem in this group. Five of six group 2 isolates had increased expression of mexX, but there was no consistent increased activity of the other efflux systems. Most remained susceptible to cephalosporins and aztreonam.
Fourteen isolates had oprD and ampC expressions similar to those of the control. Six isolates were susceptible to all ␤-lactams tested (group 3a) ( Table 2) ; efflux activity also tended to be similar to that of the controls in this group. The eight remaining isolates with oprD and ampC expressions similar to that of the control (group 3b) ( Table 2) were resistant to ertapenem, had uncharacteristically elevated MICs of meropenem (compared to imipenem), and tended to have higher MICs of aztreonam. Five of the eight had increased mexA expression. These isolates also tended to have increased expression of mexC (at least twofold times that of the control) and/or mexX. Compared to group 3a, group 3b isolates were more likely to have increased expression of two or more efflux systems (five of eight versus none of six; P ϭ 0.03). For these isolates with normal oprD and ampC expressions, a global increase of efflux activity was associated with reduced susceptibility to ertapenem, meropenem, and aztreonam. Two isolates (AM128 and DB311) did not have increased efflux pump expressions; the mechanisms of resistance in these two isolates remain undefined.
Regulatory gene studies. Ten isolates had various combinations of mutations in the regulatory gene ampR leading to amino acid substitutions (Table 3) ; none of the changes correlated with altered ampC expression. Similarly, three isolates had single base substitutions of either 87 or 143 nucleotides upstream from the ampC start codon that were not correlated with ampC expression. Nine isolates failed to have an induction of ampC following incubation with cefoxitin; seven of these isolates belonged to a single ribotype (Table 3) . Mutations in AmpR did not correlate with the ability of ampC to be induced following exposure to cefoxitin.
There were no mutations in the regulatory gene mexR that correlated with increased mexA expression. Eleven isolates had a Val 126 3Glu change in MexR; this amino acid substitution has been found in clinical isolates of P. aeruginosa and has been considered insignificant (22, 51) . There were no mutations detected in the purported Ϫ10 and Ϫ35 promoter regions for either mexR or mexA (5) . Four isolates had mutations in the distal binding site for mexR (5) ; however, mexA expression in these isolates was similar to that in isolates lacking the mutation. Two isolates had 5-bp and 4-bp deletions leading to a frameshift following Ala 145 and Gln 162 , respectively, in NalC; both of these isolates had increased expressions of mexA. Six isolates had mutations affecting NalD that correlated with increased mexA expressions; one isolate with an Asp 147 3Asn change did not have altered mexA expression. Overall, of the 11 isolates with increased expressions of mexA, eight had mutations in nalD and/or frameshift mutations in nalC that could explain the increased expressions. The remaining three isolates had mexA activity just above the limit defining increased expression (a 2.2-to 2.6-fold increase over that of the control).
All of the clinical isolates possessed a Leu 26 3Val substitution in the MexT regulatory protein, which likely did not affect MexT function (25) . The second half of the mexT gene and the intergenic region could not be amplified in seven isolates (despite attempts with different nonoverlapping primers), suggesting major mutations affecting this region. Of the seven isolates with altered MexT, all belonged to ribotype A. Compared to those of the other strains, the seven isolates with alterations in the terminal mexT gene had reduced expressions of mexE (0.20 Ϯ 0.27 versus 0.71 Ϯ 0.68; P ϭ 0.006), which is consistent with the positive regulatory effect of a functional MexT. The expressions of mexA were similar in the seven isolates with aberrant MexT; however, oprD expression was actually decreased in the seven isolates (0.27 Ϯ 0.30 versus 2.0 Ϯ 3.29; P ϭ 0.04). Finally, 10 isolates had a single base substitution in the region of the nod box-like intergenic region, where MexT is likely to bind to initiate mexEF-mexEF-oprN transcription (12) . However, the expression of mexE was not significantly different in these 10 isolates relative to the isolates that did not have this nucleotide substitution.
Fifteen isolates had no detectable mutations in mexZ or in the mexZ-mexX intergenic region (wild type). Two isolates had nucleotide substitutions leading to premature stop codons, and both had elevated levels of expression of mexX. One isolate had a nucleotide insertion causing an out-of-frame MexZ, also resulting in an increased expression of mexX. Although isolates with these major mutations in mexZ had increased expressions of mexX, their presence was certainly not a prerequisite for increased mexX transcription.
Concluding remarks. Carbapenem antibiotics are important for treating nosocomial infections due to P. aeruginosa, and the development of resistance severely hampers therapy. Understanding the mechanisms leading to carbapenem resistance in clinical isolates will be important in the development of new antimicrobial strategies. Our method of incorporating specific primers and probes for real-time RT-PCR allowed quantification of the expression of multiple genes. This is the first study to analyze the contribution of six potential mechanisms of carbapenem resistance in a large number of clinical isolates.
In the absence of an efficient carbapenemase, carbapenem resistance in P. aeruginosa has been felt to be an interplay between AmpC hyperproduction, loss of OprD, and increased expression of mexAB-oprM (13, 20) . The most consistent finding in carbapenem-resistant isolates has been the loss of OprD (33) . For imipenem, increased AmpC activity and the loss of OprD can lead to MICs of 16 g/ml (18) . However, increased expression of AmpC had little effect on meropenem, and MICs in isolates that were deficient in OprD reached only 2 to 4 g/ml (18) . Meropenem is a known substrate of the MexABOprM system, but increased expression of this system has had various effects on meropenem susceptibility (9, 13, 33) . Several conclusions can be made regarding ␤-lactam resistance in our clinical isolates. For imipenem and meropenem, decreased oprD expression was found in all resistant isolates. Most imipenem-/meropenem-resistant strains also had increased ampC and efflux pump expressions. For ertapenem, efflux pump activity appeared to be an important contributor to resistance. Most isolates that were resistant to ertapenem alone had increased activity of multiple efflux systems. Although the role of efflux systems as contributors to high-level carbapenem resistance has been questioned, our data clearly support their role in the development of ertapenem resistance. The isolates that were resistant to ertapenem alone also had reduced susceptibilities to meropenem (in relation to imipenem). This suggests a role of efflux systems for the reduced susceptibility to meropenem in this group. The contribution of efflux systems to ertapenem resistance has similarly been suggested in P. aeruginosa isolates that are susceptible to other ␤-lactams (21). Finally, increased MexAB-OprM activity was also associated with aztreonam resistance in our isolates. Meropenem and aztreonam are known substrates for MexAB-OprM (27, 50) . In some isolates, it was not possible to fully explain the basis for ␤-lactam resistance. It is possible that other mechanisms of resistance may be present in these isolates. A reduction in the outer membrane protein OprF in P. aeruginosa has been associated with increased MICs of ceftazidime and aztreonam; whether this protein is important for the entry of ertapenem remains to be determined (7) .
In carefully controlled in vitro experiments involving laboratory-derived isogenic mutants, the role of regulatory genes and the contribution of efflux pumps to antibiotic resistance have been assessed. However, these carefully designed experiments may not mimic conditions in the clinical setting. Mutations affecting mexR, selected by in vitro exposure to antibiotics (generally a fluoroquinolone and a ␤-lactam) (1, 37, 39, 40, 46) , have not been consistently observed in clinical isolates overexpressing mexAB-oprM (9, 22, 33, 51) . Our isolates overexpressing mexAB-oprM also did not appear to possess clinically significant mutations in mexR that explained the increased activity. However, most of our isolates with substantially increased expression of mexAB-oprM did have significant mutations affecting two recently described regulatory genes, nalC and nalD (4, 43) .
The roles of other regulatory proteins in clinical isolates remain to be defined. In our isolates, it is evident that regulators other than ampR (e.g., ampD) are involved with ampC expression (11, 23) . MexT, a positive regulator of the MexEFOprN system, has been implicated in the down-regulation of OprD (12) . However, isolates in this study that possessed an incomplete mexT gene had depressed expression of oprD, suggesting that other factors are involved. While disabling mutations in mexZ correlated with increased expression of mexX, many of our isolates that were hyperexpressing this efflux system did not have mutations in mexZ. It is noteworthy that 
